Unicycive Therapeutics, Inc.

NASDAQ:UNCY

Biotechnology

Healthcare
$3.57 -3.40%

-$0.24 today

Market cap
$104.19M
Beta
1.73
P/E (TTM)
-40.8
EPS (TTM)
-$0.17
52W Low $3.71High $8.74

Volume 1.39M

Average 0.65M

UNCY Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Unicycive Therapeutics, Inc.NASDAQ: UNCY

Net Debt · Q1 FY2026 · quarter ended Mar 2026

Net debt remains negative

Q1 FY2026 net debt was -$36.43M, compared with -$19.08M a year earlier.

Context

  • Net debt amounted to 56.6% of total assets at the end of Q1 FY2026, down 11.7 pp from a year earlier.
  • Net debt grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net debt keeps falling in the next quarterly balance sheet after a -91.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$36.43M-25.6% QoQ
Last fiscal yearDec 2025
-$29M-14.3% YoY
Year agoMar 2025
-$19.08M-91.0% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-91.0%——
1 year-14.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
(29M) USD
Year-over-year change
-14.3%

Net Debt vs competitors

How UNCY compares with its peers on the latest reported figures

  • Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -91.0% is the 5th highest of 10, against a peer median of -134.2%.
  • Net debt amounts to 56.6% of total assets for UNCY, versus a peer median of 45.9%.
UNCY Competitors
Net Debt for UNCY and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CBUSCibus, Inc.Mar 2026$245.83M USD+1938.7%+190.9%75.8%
RLMDRelmada Therapeutics, Inc.Mar 2026-$9.78M USD-750.3%—4.2%
HYFTMindWalk Holdings Corp.Jan 2026-CA$10.63M CAD-81872.4%—45.9%
ACRVAcrivon Therapeutics, Inc. Common StockMar 2026-$31.65M USD+11.2%—29.4%
UNCYUnicycive Therapeutics, Inc.Mar 2026-$36.43M USD-91.0%—56.6%
PMVPPMV Pharmaceuticals, Inc.Mar 2026-$38.84M USD+22.7%—40.2%
VXRTVaxart, Inc.Mar 2026-$42.78M USD-260.4%—23.8%
BMEABiomea Fusion, Inc.Mar 2026-$43.45M USD-55.5%—93.7%
CAMPCAMP4 Therapeutics CorporationMar 2026-$97.09M USD-134.2%—92.1%
IMUXImmunic, Inc.Mar 2026-$186.21M USD-1297.0%—98.1%
Peer median (excluding UNCY) —-134.2%+190.9%45.9%

Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents16.58M455K9.7M26.14M29.2M
Short-term Investments000012.07M
Net Receivables00000
Inventory00000
Other Current Assets126K159K325K939K1.17M
Total Current Assets18.41M2.64M13.4M30.95M48.96M
Property, Plant & Equipment (Net)333K174K792K720K174K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00000
Total Non-current Assets333K174K792K720K174K
Total Assets18.74M2.82M14.19M31.67M49.14M
Account Payables742K846K821K966K301K
Short-term Debt29K46K18K92K82K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities(29K)013.13M18.94M16.92M
Total Current Liabilities2.11M3.28M17.53M24.12M18.94M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities155K0466K117K0
Total Liabilities2.26M3.28M18M24.24M18.94M
Common Stock15K15K35K114K22K
Retained Earnings(15.94M)(34M)(64.54M)(101.27M)(127.83M)
Accumulated OCI0000(1K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity16.48M(466K)(3.81M)7.43M30.2M
Total Debt335K201K811K773K199K
Net Debt(16.24M)(254K)(8.89M)(25.37M)(29M)

Unicycive Therapeutics, Inc.

NASDAQ:UNCY

Intrinsic Alpha fair value

Locked

Current Price

$3.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.